La Jolla Reports US$7.2 Million in Sales of GIAPREZA in Q4 2019

- January 9th, 2020

La Jolla Pharmaceutical Company announced preliminary GIAPREZA net sales for the three and twelve months ended December 31, 2019.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced preliminary GIAPREZA (angiotensin II) net sales for the three and twelve months ended December 31, 2019.

As quoted in the press release:

For the three months ended December 31, 2019, preliminary GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018 and up 26% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.

Click here to read the full press release.

We found the top performing pharma stocks to watch this year

Find out more in our report
 

Leave a Reply